Or to treat stage 3 melanoma that cannot be removed with surgery. Cancer that cannot be removed is called unresectable. Doctors treat melanoma that can be removed with surgery (resectable) differently ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

We expect investors to focus on the sales performance of Immunocore Holdings plc’s IMCR sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...